An observational study has found that using estradiol by post menopausal women leads to lower risk of developing blood clots in leg veins (deep vein thrombosis) and clots in the lungs (pulmonary emboli) compared to use of conjugated equine estrogens.
According to a joint University of Washington (UW)-Group Health study in JAMA Internal Medicine, women patients of Group Heath who were prescribed a generic version of estradiol—a bio-equivalent estrogen—experienced fewer adverse vascular events than did those prescribed conjugated equine estrogens, a patented drug marketed as Premarin.
Birth Control Pills
Oral contraceptive or birth control pills contain hormones that prevent pregnancy. It is one of the most reliable methods of contraception.
Advertisement
"Although oral estrogens are effective for managing menopause symptoms, not enough is known about the cardiovascular safety of different oral hormone therapy products relative to each other," said first author Nicholas L. Smith, PhD. He is a professor of epidemiology at the UW School of Public Health, the director of the Veterans Affairs (VA) Seattle Epidemiologic Research and Information Center (ERIC) at the VA Puget Sound Health Care System, and an affiliate investigator at Group Health Research Institute.
To further understand the differences in risk, the researchers also measured clotting (coagulation) factors in the blood of women who did not develop a clot. The researchers found that, compared with estradiol users, conjugated equine estrogen users had levels of blood factors that made them more prone to form blood clots. The researchers also investigated other cardiovascular events:
![Safe, Effective Male Contraceptive Pill - The Long Wait]( "Safe, Effective Male Contraceptive Pill - The Long Wait")
A lot of research is going on all over the world to create a male birth control pill and soon, it could become a reality.
This project, part of the Heart and Vascular Health study, involved 384 Group Health members, aged 30-79, who were taking oral estrogen for menopause symptoms from 2003 through 2009. On February 1, 2005, Group Health's formulary switched its preferred oral estrogen from conjugated equine estrogens to estradiol. The Heart and Vascular Health study is a case-control study, where Group Health members who develop cardiovascular events are matched with control members who do not.
Source: Eurekalert
Safe, Effective Male Contraceptive Pill - The Long Wait
A lot of research is going on all over the world to create a male birth control pill and soon, it could become a reality.
Advertisement
- The risk of having a heart attack was somewhat—but not significantly—higher in women using oral conjugated equine estrogens than in those using oral estradiol.
- No difference was seen in the risk of stroke.
This project, part of the Heart and Vascular Health study, involved 384 Group Health members, aged 30-79, who were taking oral estrogen for menopause symptoms from 2003 through 2009. On February 1, 2005, Group Health's formulary switched its preferred oral estrogen from conjugated equine estrogens to estradiol. The Heart and Vascular Health study is a case-control study, where Group Health members who develop cardiovascular events are matched with control members who do not.
Source: Eurekalert
Advertisement
Advertisement
|
Advertisement
Recommended Reading
Latest Drug News
Among people with COVID-19, Paxlovid drug was found to reduce hospitalization and death risk by 90%, revealed study.
Lilly will likely maintain or increase its market share in the insulin space as the average out-of-pocket cost for its insulin products is already below the $35 price cap.
In myeloma (blood cancer) cells, cancer-promoting potential of the fatty acid binding proteins was found to determine to be a valid target for myeloma therapeutics
Acute liver failure cases dropped after the Food and Drug Administration rule to lower the dosage of acetaminophen
The new tool developed simulates tissue-specific infection of host cells of SARS-CoV-2 and then performs experiments to identify drugs for repurposing.